Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016

Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016 published by GlobalData in June, 2010. This report consists of Pages: 55 and the price starts from US $ 2000.

Introduction

Abstract

Overview

GlobalData estimated the Parkinson' s disease (PD) market to be worth $3,178m in 2009 with a projected Compound Annual Growth Rate (CAGR) of 0.9% and a projected market value to reach $3,384m in 2016.

The PD market has relatively low growth with no significant drivers besides population growth driving the volume. Barriers for the PD market are stronger in terms of both pricing (generics and me-too compounds in the market) and volume barriers such as low treatment seeking rate, low diagnosis rate and generic invasion. The PD market has relatively high unmet needs largely driven by high patient and physician expectation for products with disease modifying ability and a relatively high safety profile.

Research Methodology

GlobalData' s dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in marketing, market research, consulting background in pharmaceutical industry and advanced statistical expertise.

GlobalData adheres to the Codes of Practice of the Market Research Society and the Society of Competitive Intelligence Professionals.

All GlobalData databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

Coverage

• The objective of updating GlobalData' s coverage is to ensure that it represents the most up to date vision of the industry possible.
• Changes to the industry taxonomy are built on the basis of extensive research of company, association and competitor sources.
• Company coverage is based on three key factors: Revenues, products and media attention/innovation/ market potential.
• The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage; and
• Companies which are making the news, or which are of particular interest due to their innovative approach are prioritized.
• GlobalData aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis.
• The coverage is further streamlined and strengthened with additional inputs from GlobalData' s Expert Panel.

Table of Contents

1. Table of contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Parkinson' s Disease Market: Market Characterization

• 2.1 Overview
• 2.2 Parkinson' s Disease Market Size
• 2.3 Parkinson' s Disease Market Forecast and CAGR
• 2.4 Drivers and Barriers for the Parkinson' s Disease Market
  • 2.4.1 Drivers for the Parkinson' s Disease Market
  • 2.4.2 Barriers for the Parkinson' s Disease Market
• 2.5 Opportunity and Unmet Need
  • 2.5.1 Key Takeaway

3. Parkinson' s Disease Market: Competitive Assessment

• 3.1 Overview
• 3.2 Strategic Competitor Assessment
• 3.3 Product Profile for the Major Marketed Products in the PD Market
  • 3.3.1 Stalevo (levodopa, carbidopa, entacapone)
  • 3.3.2 Requip XL (ropinirole XL)
  • 3.3.3 Azilect (rasagiline mesylate)
  • 3.3.4 Mirapex/Sifrol/Mirapexin (pramipexole dihydrochloride)
• 3.4 Other Marketed Products for the Parkinson' s Disease Market
  • 3.4.1 Comtan (entacapone)
  • 3.4.2 Tasmar (tolcapone)
• 3.5 Key Takeaway

4. Parkinson' s Disease Market: Pipeline Assessment

• 4.1 Overview
• 4.2 Strategic Pipeline Assessment
  • 4.2.1 Technology Trends Analytic Framework
• 4.3 Parkinson' s Disease Therapeutics - Promising Drugs under Clinical Development
• 4.4 Molecule Profile for Promising Drugs under Clinical Development
  • 4.4.1 Safinamide
  • 4.4.2 Pimavanserin (ACP-103)
  • 4.4.3 PD-02
  • 4.4.4 SLV 308 (pardoprunox)
  • 4.4.5 Lisuride (patch and subcutaneous (sc) infusion)
  • 4.4.6 IPX066
• 4.5 Parkinson' s Disease Therapeutics Market - Clinical Pipeline by Mechanism of Action
• 4.6 Parkinson' s Disease Pipeline - Pipeline by Clinical Phases of Development
  • 4.6.1 Parkinson' s Disease Therapeutics - Phase III Clinical Pipeline
  • 4.6.2 Parkinson' s disease Therapeutics - Phase II Clinical Pipeline
  • 4.6.3 Parkinson' s Disease Therapeutics - Phase I Clinical Pipeline
  • 4.6.4 Parkinson' s Disease Therapeutics - Preclinical Pipeline
  • 4.6.5 Parkinson' s Disease Therapeutics - Discovery Pipeline
• 4.7 Discontinued / Suspended Drugs for Parkinson' s Disease
• 4.8 Key Takeaway

5. Parkinson' s Disease Market: Implications for Future Market Competition

6. Parkinson' s Disease Market: Future Players in the Parkinson' s Disease Market

• 6.1 Introduction
• 6.2 Merck Serono
  • 6.2.1 Overview
  • 6.2.2 CNS Portfolio
  • 6.2.3 Parkinson' s Disease Product Portfolio
• 6.3 Acadia Pharmaceuticals
  • 6.3.1 Overview
  • 6.3.2 CNS Portfolio
  • 6.3.3 Parkinson' s Disease Product Portfolio
• 6.4 Axxonis Pharma AG
  • 6.4.1 Overview
  • 6.4.2 CNS Portfolio
  • 6.4.3 Parkinson' s Disease Product Portfolio
• 6.5 Avicena Group Inc.
  • 6.5.1 Overview
  • 6.5.2 CNS Portfolio
  • 6.5.3 Parkinson' s Disease Product Portfolio
• 6.6 Solvay Pharmaceuticals
  • 6.6.1 Overview
  • 6.6.2 CNS Portfolio
  • 6.6.3 Parkinson' s Disease Product Portfolio
• 6.7 Impax Laboratories
  • 6.7.1 Overview
  • 6.7.2 CNS Portfolio
  • 6.7.3 Parkinson' s Disease Product Portfolio

7. Parkinson' s Disease Market: Appendix

• 7.1 Market Definitions
• 7.2 Abbreviations
• 7.3 Research Methodology
  • 7.3.1 Coverage
  • 7.3.2 Secondary Research
  • 7.3.3 Forecasting
  • 7.3.4 Primary Research
  • 7.3.5 Expert Panel Validation
• 7.4 Contact Us
• 7.5 Disclaimer
• 7.6 Sources

List of Tables

• Table 1: Global Parkinson' s Disease Market Revenue($m) Forecast 2001 - 2009
• Table 2: Global Parkinson' s Disease Market Revenue($m) Forecast 2009 - 2016
• Table 3: Major Marketed Products Comparison in the Parkinson' s Disease Market, 2010
• Table 4: Parkinson' s Disease Therapeutics - Most Promising Drugs under Clinical Development, 2010
• Table 5: Parkinson' s Disease Therapeutics - Phase III Clinical Pipeline, 2010
• Table 6: Parkinson' s Disease Therapeutics - Phase II Clinical Pipeline, 2010
• Table 7: Parkinson' s Disease Therapeutics - Phase I Clinical Pipeline, 2010
• Table 8: Parkinson' s Disease Therapeutics - Preclinical Pipeline, 2010
• Table 9: Parkinson' s Disease Therapeutics - Discovery Pipeline, 2010
• Table 10: List of Discontinued Drugs for Parkinson' s Disease, 2010
• Table 11: Merck Serono - CNS Marketed Products, 2010
• Table 12: Merck Serono - CNS Pipeline Products, 2010
• Table 13: Acadia Pharmaceuticals - CNS Pipeline Products, 2010
• Table 14: Axxonis Pharma AG - CNS Pipeline Products, 2010
• Table 15: Avicena Group Inc. - CNS Pipeline Products, 2010
• Table 16: Solvay Pharmaceuticals - CNS Marketed Products, 2010
• Table 17: Solvay Pharmaceuticals - CNS Pipeline Products, 2010
• Table 18: Impax Laboratories - CNS Marketed Products, 2010
• Table 19: Impax Laboratories - CNS Pipeline Products, 2010

List of Figures

• Figure 1: Global Parkinson' s Disease Market Revenue($m) Forecast 2001 - 2009
• Figure 2: Global Parkinson' s Disease Market Revenue($m) Forecast 2009 - 2016
• Figure 3: Opportunity and Unmet Need in the Parkinson' s Disease Market, 2010
• Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Parkinson' s Disease, 2010
• Figure 5: Technology Trends Analytic Framework of the Parkinson' s Disease Pipeline, 2010
• Figure 6: Technology Trends Analytic Framework of the Parkinson' s Disease Pipeline - Description, 2010
• Figure 7: Parkinson' s Disease Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010
• Figure 8: Parkinson' s Disease Pipeline - Pipeline by Clinical Phases of Development, 2010
• Figure 9: Implications for Future Market Competition in the Parkinson' s Disease Market, 2010
• Figure 10: Parkinson' s Disease Therapeutics Market - Clinical Pipeline by Company, 2010
• Figure 11: GlobalData Methodology
• Figure 12: GlobalData Market Forecasting Model

Related Reports